IMpower132 Casts More Doubt On Roche's Tecentriq In First-Line NSCLC
Executive Summary
The lack of significant overall survival benefit in IMpower132 may be related to PD-L1 expression – though the dataset is incomplete – or the higher dose of chemo used in the trial.
You may also be interested in...
An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer
CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Roche's Tecentriq Positive But Not Perfect In IMpower130 First-line Lung Cancer Study
Combination with Abraxane demonstrates an overall survival benefit on top of progression-free survival, but Merck's competing Keytruda has set a high benchmark for first-line metastatic lung cancer.